7:03AM Optimer Pharma: CMS grants new technology add-on payment to DIFICID for treatment of clostridium difficile-associated diarrhea (OPTR) 12.88 : Co announced that the Centers for Medicare & Medicaid Services (CMS) has granted a new technology add-on payment for DIFICID tablets administered in the inpatient setting to treat Clostridium difficile-associated diarrhea. The NTAP payment will provide hospitals with a payment, in addition to the standard-of-care DRG reimbursement, of up to 50% of the cost of DIFICID for a period of two to three years, effective in the fiscal year starting on October 1, 2012. For 2013, CMS has assigned a maximum payment of $868.00. The NTAP payment is available to hospitals only for individual patient cases that are more costly than the average DRG charges.
Market Data 
Markets 
AI
